Setrusumab
Based on 1 Customer Validation
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.9%
- CAS No.: 1847394-95-9
- 분자량:143.44 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG2 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
SOST/Sclerostin
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week-old female immune-compromised CB-17/lcr-Prkdcscid/Rj mice with MDA-MB-231 breast cancer cells injection[1]
-
Dosage:100 mg/kg
-
Administration:Intravenous injection; 100 mg/kg once a week for 4 weeks
-
Result:Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 lambda
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Setrusumab on AHC2 biosensor, can bind SOST Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78209) with an affinity constant of 8.123E-11 M as determined in BLI assay. -
Immobilized SOST Protein, Human (HEK293, His, HY-P70756) can bind Setrusumab. The EC50 for this effect is 12.07 ng/mL.
Chemical Information
-
CAS No. 1847394-95-9
-
Appearance Liquid
-
분자량 143.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Setrusumab]
-
Synonyms
BPS 804
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Mesenchymal stromal/stem cell osteogenic differentiation
Mesenchymal stromal/stem cells can be induced toward an osteoblast-like lineage in vitro by culture in osteogenic medium containing dexamethasone, ascorbic acid or ascorbate-2-phosphate, and β-glycerophosphate; the differentiation process is commonly evaluated by alkaline phosphatase activity, osteogenic marker expression, collagenous matrix formation, and calcium-rich matrix mineralization. The main readouts are alkaline phosphatase activity as an early osteogenic marker and Alizarin Red S staining as a calcium-deposit readout for mineralized extracellular matrix; Alizarin Red S can be inspected microscopically or extracted and measured colorimetrically at 405 nm.
순도&문서
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)